環(huán)保在線
詳細介紹
當(dāng)化學(xué)家為制藥與生物制藥產(chǎn)品開發(fā)分析方法時，選擇具有重現(xiàn)能力的HPLC柱至關(guān)重要。被選擇的色譜柱需要在這個新的藥物產(chǎn)品的整個生命周期中都能提供一致的色譜分析結(jié)果，而Symmetry色譜柱顯示出跨越多年的重現(xiàn)性。確保重現(xiàn)性是我們在供應(yīng)Symmetry色譜柱時的要素。如此優(yōu)秀的重現(xiàn)性，則來自于我們持續(xù)不懈的致力于HPLC色譜柱行業(yè)內(nèi)的指標控制。Symmetry色譜柱，由高純硅膠、嚴格控制的生產(chǎn)工藝和色譜柱裝填工藝所得，為色譜工作者提供、最重現(xiàn)的HPLC色譜柱。
產(chǎn)品技術(shù)與性能，為硅膠基質(zhì)的C18和C8色譜柱樹立了新的行業(yè)標準
■精心設(shè)計填料的物理和化學(xué)性質(zhì)，以確保容載量與分辨率；尤其有利于在低至中等pH條件下分離純化可電離化合物。
■耐受低pH條件，鍵合相穩(wěn)定牢固，柱壽命長。
■結(jié)合于OBD™制備柱設(shè)計，確保柱效與最長柱壽命。
■填料起始于有機硅合成，繼以技術(shù)的表面化學(xué)修飾，所有制造工藝與過程均依從cGMP規(guī)范，確保產(chǎn)品的高純品質(zhì)、高優(yōu)性能、與高度可靠。
Validation and clinical application of a high performance liquid chromatography tandem mass spectrometry (LC-MS/MS) method for the quantitative determination of 10 anti-retrovirals in human peripheral blood mononuclear cells
This paper reports the validation of a liquid chromatography tandem mass spectrometry (LC-MS/MS) method that allows the quantification of 10 antiretroviral (ARV) drugs in peripheral blood mononuclear cells (PBMCs) using 6 different isotopic internal standards (IS) and its clinical application. PBMCs are isolated from blood by density gradient centrifugation and drugs are extracted with a 60% methanol (MeOH) solution containing the 6 IS. The cell extract is then injected in the HPLC system and analytes are separated on a Symmetry Shield RP18 2.1 mm × 50 mm column. The different molecules are then detected by MS/MS in electrospray positive or negative ionisation modes and data are recorded using the multiple reaction monitoring (MRM) mode. Calibration curves are constructed in the range of 0.25–125 ng/ml of cell extract by a 1/x2 weighted quadratic regression. The regression coefficients obtained are always greater than 0.99 and back calculated values always comprised in the range of ±15% from their nominal concentration. Mean extraction recoveries are greater than 80% for all analytes and the method is accurate and precise with CV and bias lower than 9.4%. The lower limits of quantification (LLOQ) of the different drugs range from 0.0125 to 0.2 ng/ml of cell extract. This method was successfully applied to a cohort of 98 HIV-infected patients treated with Kaletra®(400/100 mg of lopinavir/ritonavir (LPV/RTV) twice a day, n = 48) or with Stocrin® (600 mg once a day, n = 50) and has been tested for cellular quantification of tipranavir (TPV) in 2 patients treated with Aptivus®(500 mg twice a day). The patients treated by Kaletra® showed mean cell-associated concentrations (CC) of 1819.0 and 917.2 ng/ml, for LPV and RTV, respectively. Patients treated with Stocrin® showed mean CC of 2388.11 ng/ml while both patients under Aptivus® showed TPV CC of 4322.7 and 1078.0 ng/ml, respectively. This method can be used to analyze ARV drug concentrations within the target tissue.
品名 | 規(guī)格 | 編號 |
Symmetry C8 Column | 100?, 5 µm, 4.6 mm X 250 mm, 1/pkg | 186007715 |
Symmetry C8 Column | 100?, 3.5 µm, 3 mm X 100 mm, 1/pkg | WAT054270 |
Symmetry C8 Column | 100?, 3.5 µm, 3 mm X 150 mm, 1/pkg | 186000698 |
Symmetry C8 Column | 100?, 5 µm, 3 mm X 150 mm, 1/pkg | 186000697 |
Symmetry C8 Column | 100?, 3.5 µm, 4.6 mm X 50 mm, 1/pkg | WAT054230 |
Symmetry C8 Column | 100?, 5 µm, 4.6 mm X 150 mm, 1/pkg | WAT200620 |
Symmetry C8 Column | 100?, 3.5 µm, 4.6 mm X 30 mm, 1/pkg | WAT045995 |
Symmetry C8 Column | 100?, 5 µm, 4.6 mm X 100 mm, 1/pkg | 186002087 |
Symmetry C8 Column | 100?, 3.5 µm, 2.1 mm X 50 mm, 1/pkg | 186002083 |
Symmetry C8 Column | 100?, 3.5 µm, 2.1 mm X 100 mm, 1/pkg | WAT200624 |
Symmetry C8 Column | 100?, 5 µm, 3 mm X 250 mm, 1/pkg | WAT058961 |
Symmetry C8 Column | 100?, 5 µm, 2.1 mm X 150 mm, 1/pkg | 186000691 |
Symmetry C8 Column | 100?, 3.5 µm, 2.1 mm X 30 mm, 1/pkg | WAT056955 |
Symmetry C8 Column | 100?, 3.5 µm, 4.6 mm X 75 mm, 1/pkg | WAT058977 |
Symmetry C8 Column | 100?, 5 µm, 2.1 mm X 50 mm, 1/pkg | WAT066200 |
Symmetry C8 Column | 100?, 5 µm, 4.6 mm X 50 mm, 1/pkg | 186000212 |
Symmetry C8 Column | 100?, 5 µm, 2.1 mm X 100 mm, 1/pkg | WAT054245 |
Symmetry C8 Column | 100?, 3.5 µm, 4.6 mm X 150 mm, 1/pkg | 186002609 |
Symmetry C8 Column | 100?, 3.5 µm, 2.1 mm X 150 mm, 1/pkg | WAT094237 |
Symmetry C8 Column | 100?, 5 µm, 3.9 mm X 150 mm, 1/pkg | WAT106011 |
Symmetry C8 Column | 100?, 3.5 µm, 4.6 mm X 100 mm, 1/pkg | WAT046970 |
Symmetry C8 Method Validation Kit | 100?, 3.5 µm, 4.6 mm X 150 mm, 3/pkg | WAT200630 |
Symmetry C8 Method Validation Kit | 100?, 5 µm, 3.9 mm X 150 mm, 3/pkg | 186000712 |
Symmetry C8 Method Validation Kit | 100?, 5 µm, 4.6 mm X 150 mm, 3/pkg | WAT066225 |
Symmetry C8 Method Validation Kit | 100?, 5 µm, 4.6 mm X 250 mm, 3/pkg | 186000238 |
Symmetry C8 Prep Column | 100?, 7 µm, 19 mm X 300 mm, 1/pkg | WAT066204 |
Symmetry C8 Prep Column | 100?, 5 µm, 19 mm X 100 mm, 1/pkg | WAT200661 |
Symmetry C8 Prep Column | 100?, 5 µm, 7.8 mm X 50 mm, 1/pkg | WAT046955 |
Symmetry C8 Prep Column | 100?, 5 µm, 7.8 mm X 100 mm, 1/pkg | 186000214 |
Symmetry C8 Prep Column | 100?, 7 µm, 7.8 mm X 300 mm, 1/pkg | 186000215 |
Symmetry C8 Prep Column | 100?, 5 µm, 30 mm X 100 mm, 1/pkg | WAT054435 |
Symmetry C8 Prep Column | 100?, 5 µm, 30 mm X 50 mm, 1/pkg | 186007733 |
Symmetry C8 Prep Column | 100?, 7 µm, 7.8 mm X 150 mm, 1/pkg | 186007737 |
Symmetry C8 Prep Column | 100?, 7 µm, 19 mm X 150 mm, 1/pkg | 186007739 |
環(huán)保在線